Premium
Actein activates stress‐ and statin‐associated responses and is bioavailable in Sprague‐Dawley rats
Author(s) -
Einbond Linda Saxe,
Soffritti Morando,
Esposti Davide Degli,
Park Taesik,
Cruz Erica,
Su Tao,
Wu Hsanau,
Wang Xiaomei,
Zhang YuJing,
Ham Justin,
Goldberg Ira J.,
Kronenberg Fredi,
Vladimirova Antoaneta
Publication year - 2009
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.2009.00673.x
Subject(s) - pharmacology , statin , endocrinology , arachidonic acid , bioavailability , black cohosh , cholesterol , cholesterol 7 alpha hydroxylase , cyp2c8 , medicine , pharmacokinetics , gene expression , hmg coa reductase , chemistry , biochemistry , gene , cytochrome p450 , metabolism , reductase , menopause , cyp3a4 , enzyme
The purpose of this study was to assess in rats the pharmacological parameters and effects on gene expression in the liver of the triterpene glycoside actein. Actein, an active component from the herb black cohosh, has been shown to inhibit the proliferation of human breast cancer cells. To conduct our assessment, we determined the molecular effects of actein on livers from Sprague‐Dawley rats treated with actein at 35.7 mg/kg for 6 and 24 h. Chemogenomic analyses indicated that actein elicited stress and statin‐associated responses in the liver; actein altered expression of cholesterol and fatty acid biosynthetic genes, p53 pathway genes, CCND1 and ID3. Real‐time RT‐PCR validated that actein induced three time‐dependent patterns of gene expression in the liver: (i) a decrease followed by a significant increase of HMGCS1, HMGCR, HSD17B7, NQO1, S100A9; (ii) a progressive increase of BZRP and CYP7A1 and (iii) a significant increase followed by a decrease of CCND1 and ID3. Consistent with actein’s statin‐ and stress‐associated responses, actein reduced free fatty acid and cholesterol content in the liver by 0.6‐fold at 24 h and inhibited the growth of human HepG2 liver cancer cells. To determine the bioavailability of actein, we collected serum samples for pharmacokinetic analysis at various times up to 24 h. The serum level of actein peaked at 2.4 μg/mL at 6 h. Actein’s ability to alter pathways involved in lipid disorders and carcinogenesis may make it a new agent for preventing and treating these major disorders.